Comparing second-line treatments for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study reviews medical records from people with advanced lung cancer who have already tried immunotherapy and their cancer got worse. The goal is to compare different second-line treatments to see which might work better after immunotherapy stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be cured with current treatments.
- Your first treatment for advanced lung cancer included an immunotherapy drug (checkpoint inhibitor).
- Your cancer got worse during or after that first immunotherapy treatment.
- You received at least 3 cycles (doses) of that first immunotherapy.
- Your medical records include complete details like age, smoking history, tumor location, and scan results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
This trial compares two approaches after initial chemotherapy and immunotherapy for advanced non-small cell lung cancer: giving additional local treatment (like surgery or radiation) to remaining spots versus continuing immunotherapy. It aims to see which strategy better controls the cancer.
This study compares getting both chemotherapy and immunotherapy versus immunotherapy alone for older adults with advanced lung cancer. The goal is to see which approach is more effective and tolerable for people aged 70 and older.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.